# A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

> **NCT05463731** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 1667 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Remternetug (IV)
- **DRUG:** Remternetug (SC)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05463731
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2024-04-24
- **Final completion:** 2026-03
- **Target enrollment:** 1667 (ACTUAL)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05463731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05463731, "A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05463731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*